Inhibikase Q2 Loss Hits $19.6M as Trial Costs Mount
IKT sits 84% above its 52-week low of $1.33.
Summary
Inhibikase reported a Q2 net loss of $19.6 million, or $0.11 per share, driven by higher R&D and SG&A expenses tied to the Phase 3 IMPROVE-PAH trial. The company raised $50 million in July from RA Capital, extending its cash runway through the expected topline data readout. The FDA granted orphan drug designation for IKT-001 in July, offering potential market exclusivity. The widening loss underscores the cash burn rate as the pivotal trial advances, but the recent financing provides a buffer. Key upcoming catalyst: Phase 3 topline data, though no specific date is provided.
At the time of this announcement, IKT was trading at $2.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $323.5M. The 52-week trading range was $1.33 to $2.53. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.